An Open-label, Balanced, Randomized, Two-period, Crossover, Single Dose Study to Compare the Bioavailability of PanCytoVir™ Oral Suspension (100mg/ml), in Healthy, Adult, Human Subjects Under Fed and Fasting Conditions
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Probenecid (Primary)
- Indications COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors TrippBio
Most Recent Events
- 21 Nov 2024 Status changed from not yet recruiting to completed.
- 08 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 Oct 2024.
- 08 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2024.